Adaptation, reliability and validity of health-related quality of life questionnaires: Disabkids chronic and specific diabetes disease in children and adolescents with diabetes mellitus type 1.

Autor: Alonso Rubio P; Unidad de Endocrinología Pediátrica, Hospital Universitario Marqués de Valdecilla, Santander, Spain. Electronic address: pabloalonsorubio@gmail.com., Bahíllo Curieses MP; Unidad de Endocrinología Pediátrica, Hospital Clínico Universitario de Valladolid, Valladolid, Spain., Prieto Matos P; Unidad de Endocrinología Pediátrica, Hospital Universitario de Salamanca, Salamanca, Spain., Bertholt Zuber ML; Unidad de Endocrinología Pediátrica, Hospital Universitario Marqués de Valdecilla, Santander, Spain., Martín Alonso MM; Unidad de Endocrinología Pediátrica, Hospital Universitario de Salamanca, Salamanca, Spain., Murillo Vallés M; Unidad de Endocrinología Pediátrica, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain., Chueca Guindulain MJ; Unidad de Endocrinología Pediátrica, Complejo Hospitalario de Navarra, Pamplona, Spain., Berrade Zubiri S; Unidad de Endocrinología Pediátrica, Complejo Hospitalario de Navarra, Pamplona, Spain., Huidobro Fernández B; Unidad de Endocrinología Pediátrica, Hospital Universitario de Cabueñes, Gijón, Spain., Prado Carro AM; Unidad de Endocrinología Pediátrica, Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain., Rodríguez Estévez A; Unidad de Endocrinología Pediátrica, Hospital Universitario Cruces, Barakaldo, Spain; BIOCRUCES, Barakaldo, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain., Rica Echevarría I; Unidad de Endocrinología Pediátrica, Hospital Universitario Cruces, Barakaldo, Spain; BIOCRUCES, Barakaldo, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain., Grau Bolado G; Unidad de Endocrinología Pediátrica, Hospital Universitario Cruces, Barakaldo, Spain; BIOCRUCES, Barakaldo, Bizkaia, Spain; Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Spain., Díez López I; Unidad de Endocrinología Pediátrica, Hospital Universitario Araba, Vitoria-Gasteiz, Spain., Fernández Ramos MC; Unidad de Endocrinología Pediátrica, Hospital Universitario de Basurto, Bilbao, Spain., Rodríguez Dehli C; Unidad de Endocrinología Pediátrica, Hospital Universitario San Agustín, Avilés, Spain., Riaño-Galán I; AGC de Pediatría, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Biosanitaria del Principado de Asturias (ISPA), Universidad de Oviedo, Oviedo, Spain; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Spain.
Jazyk: angličtina
Zdroj: Endocrinologia, diabetes y nutricion [Endocrinol Diabetes Nutr (Engl Ed)] 2023 Sep; Vol. 70 Suppl 3, pp. 18-26. Date of Electronic Publication: 2023 Aug 17.
DOI: 10.1016/j.endien.2023.07.004
Abstrakt: Introduction: It is recommended to periodically evaluate the health-related quality of life (HRQoL) in children and adolescents with type 1 diabetes mellitus (DM1). Despite this, no specific paediatric HRQoL instrument for DM1 has been validated in Spanish.
Objectives: Multicentre, prospective descriptive study in children and adolescents with DM1 with the aim of carrying out cross-cultural adaptation to Spanish and evaluating the reliability and validity of the DISABKIDS chronic disease and diabetes-specific HRQoL questionnaires, using reverse translation.
Material and Methods: Sociodemographic variables were compiled together with the most recent capillary glycated haemoglobin (HbA1c) value and HRQoL questionnaires were handed out to 200 Spanish children and adolescents with DM1 aged between 8 and 18 years of age under evaluation in 12 different hospitals.
Results: The mean score on the HRQoL questionnaire (patient version) for chronic disease was 80.32 (13.66), being significantly lower (P = .04) in patients with a shorter duration of the disease (≤5 years): 78.34 (13.70) vs. 82.60 (13.36). The mean score of the DM1-specific modules was: 60.81 (16.23) for disease impact and 65.59 (26.19) for treatment impact. The mean HbA1c value was 7.08 (0.79), with no differences (P > .05) noted in the mean score of the HRQoL instruments in patients with HbA1c ≤7% vs. HbA1c >7%. The Cronbach α value varied between 0.72 and 0.90.
Conclusions: The Spanish versions of the DISABKIDS HRQoL instruments meet the proposed objectives of semantic equivalence and internal consistency, making it possible to periodically assess HRQoL in these patients. The good average glycaemic control presented by the patients may explain why no difference was found in the HRQoL instruments based on the HbA1c value.
(Copyright © 2022 The Author(s). Published by Elsevier España, S.L.U. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: